Format

Send to

Choose Destination

See 1 citation in Early Hum Dev 2016:

Early Hum Dev. 2016 Aug;99:27-30. doi: 10.1016/j.earlhumdev.2016.05.010. Epub 2016 Jul 4.

Safety of histamine-2 receptor blockers in hospitalized VLBW infants.

Author information

1
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: aromaine@live.unc.edu.
2
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: daniel.ye@duke.edu.
3
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: aosterrr@gmail.com.
4
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: francia.fang@duke.edu.
5
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: octaviousjohnson33@yahoo.com.
6
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: tsblake015@gmail.com.
7
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: danny.benjamin@dm.duke.edu.
8
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: michael.cotten@duke.edu.
9
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: danielatestoni@gmail.com.
10
Pediatrix-Obstetrix Center for Research and Education, Sunrise, FL,USA. Electronic address: Reese_H_Clark@us.MEDNAX.com.
11
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: vivian.chu@duke.edu.
12
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: brian.smith@dm.duke.edu.
13
Duke Clinical Research Institute, Durham, NC, USA. Electronic address: christoph.hornik@dm.duke.edu.

Abstract

BACKGROUND:

Histamine-2 receptor (H2) blockers are often used in very low birth weight infants despite lack of population specific efficacy and safety data.

AIMS:

We sought to describe safety and temporal trends in histamine-2 receptor (H2) blocker use in hospitalized very low birth weight (VLBW) infants.

STUDY DESIGN:

We conducted a retrospective cohort study using a clinical database populated by an electronic health record shared by 348 neonatal intensive care units in the United States.

SUBJECTS:

We included all VLBW infants without major congenital anomalies.

OUTCOME MEASURES:

We used multivariable logistic regression with generalizing estimating equations to evaluate the association between days of H2 blocker exposure and risk of: 1) death or necrotizing enterocolitis (NEC); 2) death or sepsis; and 3) death, NEC, or sepsis.

RESULTS:

Of 127,707 infants, 20,288 (16%) were exposed to H2 blockers for a total of 6,422,352days. Median gestational age for infants exposed to H2 blockers was 27weeks (25th 75th percentile 26, 29). H2 blocker use decreased from 18% of infants in 1997 to 8% in 2012 (p<0.001). On multivariable analysis, infants were at increased risk of the combined outcome of death, NEC, or sepsis on days exposed to H2 blockers (odds ratio=1.14) (95% confidence interval 1.08, 1.19).

CONCLUSIONS:

H2 blocker use is associated with increased risk of the combined outcome of death, NEC, or sepsis in hospitalized VLBW infants.

KEYWORDS:

H2 blockers; Histamine-2 receptor antagonists; Infants; Necrotizing enterocolitis

PMID:
27390109
PMCID:
PMC4969147
DOI:
10.1016/j.earlhumdev.2016.05.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center